GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Raphael Pharmaceutical Inc (OTCPK:RAPH) » Definitions » ROE %

Raphael Pharmaceutical (Raphael Pharmaceutical) ROE % : -2,682.93% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Raphael Pharmaceutical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Raphael Pharmaceutical's annualized net income for the quarter that ended in Mar. 2024 was $-2.20 Mil. Raphael Pharmaceutical's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $0.08 Mil. Therefore, Raphael Pharmaceutical's annualized ROE % for the quarter that ended in Mar. 2024 was -2,682.93%.

The historical rank and industry rank for Raphael Pharmaceutical's ROE % or its related term are showing as below:

RAPH' s ROE % Range Over the Past 10 Years
Min: -77157.89   Med: -2870.09   Max: -688.47
Current: -77157.89

During the past 4 years, Raphael Pharmaceutical's highest ROE % was -688.47%. The lowest was -77,157.89%. And the median was -2,870.09%.

RAPH's ROE % is ranked worse than
100% of 993 companies
in the Drug Manufacturers industry
Industry Median: 4.2 vs RAPH: -77157.89

Raphael Pharmaceutical ROE % Historical Data

The historical data trend for Raphael Pharmaceutical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Raphael Pharmaceutical ROE % Chart

Raphael Pharmaceutical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROE %
- -3,821.18 -2,870.09 -688.47

Raphael Pharmaceutical Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,177.32 - - -2,329.17 -2,682.93

Competitive Comparison of Raphael Pharmaceutical's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Raphael Pharmaceutical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Raphael Pharmaceutical's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Raphael Pharmaceutical's ROE % distribution charts can be found below:

* The bar in red indicates where Raphael Pharmaceutical's ROE % falls into.



Raphael Pharmaceutical ROE % Calculation

Raphael Pharmaceutical's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-1.284/( (0.106+0.267)/ 2 )
=-1.284/0.1865
=-688.47 %

Raphael Pharmaceutical's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-2.2/( (0.267+-0.103)/ 2 )
=-2.2/0.082
=-2,682.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


Raphael Pharmaceutical  (OTCPK:RAPH) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-2.2/0.082
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-2.2 / 0)*(0 / 0.346)*(0.346 / 0.082)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*4.2195
=ROA %*Equity Multiplier
=N/A %*4.2195
=-2,682.93 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-2.2/0.082
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-2.2 / -2.2) * (-2.2 / -2.188) * (-2.188 / 0) * (0 / 0.346) * (0.346 / 0.082)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0055 * N/A % * 0 * 4.2195
=-2,682.93 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Raphael Pharmaceutical ROE % Related Terms

Thank you for viewing the detailed overview of Raphael Pharmaceutical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Raphael Pharmaceutical (Raphael Pharmaceutical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
4 Lui Paster, Tel Aviv-Jaffa, ISR, 6803605
Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil.
Executives
Joseph Press director 4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Shlomo Pilo director, 10 percent owner, officer: Chief Executive Officer 4 LUI PASTER, TEL AVIV L3 6803605
Hayon Igal Louria director, officer: Chief Technology Officer 4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Yehuda Eliya director 4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Robert B Catell director 62 OSBORNE ROAD, GARDEN CITY NY 11530
Elisha Yanay director C/O ADVANCED TECHNOLOGY ACQUISITION CORP, 14 A ACHIMEIR STREET, RAMAT GAN L3 52587
Yacov A Shamash director
Guy Ofir director, 10 percent owner, officer: President 40 BAZ STREET, KARMIEL L3 20100
Emanuel Cohen director, 10 percent owner, officer: Secretary Treasurer Director 51 BILU STREET, RA'ANANA L3 00000

Raphael Pharmaceutical (Raphael Pharmaceutical) Headlines

No Headlines